• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

4.055 -0.175 (-4.14%)
Streaming Delayed Price Updated: 1:56 PM EDT, Jun 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,170,476
Open 4.290
Bid (Size) 4.050 (5,100)
Ask (Size) 4.060 (6,300)
Prev. Close 4.230
Today's Range 4.040 - 4.350
52wk Range 1.660 - 5.630
Shares Outstanding 305,252,194
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
Today 9:01 EDT
From Biotech Insider
Via GlobeNewswire
News headline image
Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
June 03, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+60.9%
+60.9%
1 Month
+12.0%
+12.0%
3 Month
-25.0%
-25.0%
6 Month
+75.5%
+75.5%
1 Year
+83.5%
+83.5%

More News

Read More
News headline image
Iovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For? ↗
June 02, 2026
Via The Motley Fool
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances Delivery-Focused Oncology Platform Amid Growing Interest in Drug-Delivery Technologies
June 01, 2026
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Iovance Biotherapeutics (NASDAQ:IOVA) Reports Q1 Revenue Beat and Raised Guidance, Yet Stock Slips Pre-Market ↗
May 07, 2026
Via Chartmill
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) Reports Q4 Revenue Beat and Strong Clinical Progress ↗
February 24, 2026
Via Chartmill
How Advanced Drug Delivery Could Improve Existing Cancer Treatments
June 01, 2026
Via Investor Brand Network
News headline image
How Advanced Drug Delivery Could Improve Existing Cancer Treatments
June 01, 2026
From BioMedWire
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001
June 01, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
May 22, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Present at Upcoming Conference
May 21, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance (IOVA) Q1 2026 Earnings Transcript ↗
May 08, 2026
Via The Motley Fool
News headline image
Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
May 07, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
This Beaten-Down Growth Stock Could Soar 165%, According to Wall Street ↗
May 02, 2026
Via The Motley Fool
Topics Death
News headline image
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
April 27, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare? ↗
April 10, 2026
Via The Motley Fool
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
March 20, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments ↗
March 12, 2026
Via MarketBeat
News headline image
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 ↗
March 05, 2026
Via The Motley Fool
News headline image
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? ↗
March 05, 2026
Via Stocktwits
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences
February 26, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why ↗
February 25, 2026
Via Stocktwits
Topics Earnings
Curious about the most active stocks on Tuesday? ↗
February 24, 2026
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
February 24, 2026
Via Chartmill
News headline image
Iovance (IOVA) Q4 2025 Earnings Call Transcript ↗
February 24, 2026
Via The Motley Fool
Topics Earnings

Frequently Asked Questions

Is Iovance Biotherapeutics, Inc. - Common Stock publicly traded?
Yes, Iovance Biotherapeutics, Inc. - Common Stock is publicly traded.
What exchange does Iovance Biotherapeutics, Inc. - Common Stock trade on?
Iovance Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock?
The ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock is IOVA on the Nasdaq Stock Market
What is the current price of Iovance Biotherapeutics, Inc. - Common Stock?
The current price of Iovance Biotherapeutics, Inc. - Common Stock is 4.055
When was Iovance Biotherapeutics, Inc. - Common Stock last traded?
The last trade of Iovance Biotherapeutics, Inc. - Common Stock was at 06/08/26 01:56 PM ET
What is the market capitalization of Iovance Biotherapeutics, Inc. - Common Stock?
The market capitalization of Iovance Biotherapeutics, Inc. - Common Stock is 1.24B
How many shares of Iovance Biotherapeutics, Inc. - Common Stock are outstanding?
Iovance Biotherapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap